Celgene Sr Director, Global Health Economics/Outcomes Research in Summit, New Jersey
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
Senior Director, Global Health Economics/Outcomes ResearchSummit, NJ
The Senior Director of Global HEOR, I&I is responsible for all Global HEOR strategic plans, research, publications, and customer-facing resources to support I&I in-market and development compounds.
Responsibilities will include, but are not limited to, the following:
Develop and execute I&I HEOR research and publication strategy to support product the value proposition for Celgene I&I products
Conduct and lead HEOR research including prospective and retrospective observational studies, cost effectiveness models, comparative effectiveness research, patient-reported outcomes research, meta-analyses and systematic reviews
Design customer facing tools such as reactive and proactive presentations to enable customers to comprehend the economic benefits and budget impact of I&I products
Assure compliance of evidence-based medicine and principles for economic assessment
Represent Market Access on key cross-functional teams
Assure timely execution of HEOR projects and tight management of budget
Arrange data sharing forum among affiliates and global teams
Support Access Strategy brand leaders in identification and implementation of appropriate PRO instruments to support patient benefits in clinical studies
Maintain awareness of global HEOR requirements, PRO guidelines, regulatory legislation, best practices, and case studies
Advanced Scientific Degree (PhD, MD, PharmD) required.
At least 10 years of HEOR experience in the pharmaceutical industry. Background in immunology area such as psoriasis, psoriatic arthritis, MS, IBD is preferred but not required
Strong leadership skills
High level strategic thinking, problem solving and decision-making skills
Experienced in influencing strategy with internal and external customer audiences
Excellent analytical skills, including in-depth knowledge of health outcomes, PROs, retrospective database and evidence-based medicine methodologies.
Experience in managing multiple projects across a variety of health outcomes methodologies and therapeutic areas.
Excellent communication, collaboration, interpersonal, and organizational/administrative skills
Background in immunology area such as psoriasis, psoriatic arthritis, MS, IBD is preferred but not required
Willing to travel, both within US and international, approximately 20%
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.